182 results about "K-alpha" patented technology

The invention discloses a crystal form B. The crystal form B is characterized in that Cu-K alpha radiation is used, X-RPD (X-ray powder diffraction) indicated by the 2 theta angle has diffraction peaks at 6.4+/-0.2 degrees, 7.9+/-0.2 degrees, 8.7+/-0.2 degrees, 9.8+/-0.2 degrees, 10.0+/-0.2 degrees and 17.0+/-0.2 degrees. The crystal form B can be prepared on a large scale safely and purified, can be stored stably, does not have moisture absorption, is very suitable for preparation of an inhalable preparation and has good compatibility with excipients such as lactose, starch and the like.

The invention relates to vortioxetine hydrobromide and in particular relates to a crystal of 1-[2-(2,4-dimethylphenylthioxo)phenyl] piperazine hydrobromide. The crystal uses Cu-K alpha radiation. In a powder X-ray diffraction pattern shown by a 2theta angle, diffraction peaks exist at about 6.89 degrees, 9.73 degrees, 13.78 degrees and 14.62 degrees. The invention also relates to a preparation method of the crystal and a drug composition containing the compound. The compound shows the serotonin reabsorption inhibitory activity, has activities towards a serotonin receptor 1A (5-HT1A) and a serotonin receptor 3 (5-HT3), can be used for treating CNS (central nervous system)-related diseases, in particular can be used for treating depressive disorder, especially major depressive disorder of adults, and can be also used for treating other CNS-related diseases.

A recording material comprising a support and a thermosensitive element containing silver behenate, an organic reducing agent therefor in thermal working relationship therewith and a binder, wherein the silver behenate is not associated with mercury and/or lead ions and when the recording material is irradiated with a copper K alpha 1 X-ray source the ratio, normalized to a quantity of silver in the recording material of 1 g per m2 thereof, of the sum of the peak heights of the X-ray diffraction lines attributable to silver behenate at Bragg angles, 2 THETA , of 6.01 DEG , 7.56 DEG , 9.12 DEG , 10.66 DEG , 12.12 DEG and 13.62 DEG to the sum of the peak heights of the X-ray diffraction lines at Bragg angles, 2 THETA , of 25.60 DEG , 35.16 DEG and 43.40 DEG of NIST standard 1976, rhombohedral Al2O3, determined with the same X-ray diffractometer in the same state of adjustment, is greater than 0.85; production processes for particles of substantially light-insensitive organic silver salt comprising silver behenate with these X-ray characteristics in the presence and substantial absence of organic solvent.

The invention provides a facial expression recognition method based on feature point vectors and a texture deformation energy parameter. The method comprises the following steps: 1, respectively carrying out feature point positioning on neutral expressions and extreme expressions at a beginning end of a facial expression sequence by an AAM (Automatic Acoustic Management) tool of an OPENCV (Open Source Computer Vision Library); 2, forming feature point vectors with the selected 26 feature points to suit facial expression recognition, dividing the feature point vectors into a Euclidean distance d (representing a size) between the feature points and an included angle alpha (representing a direction) of connecting lines, calculating a distance coefficient ratio kd of the feature points according to d and alpha, and subtracting a redundant part kl to obtain kd - final (k alpha-final can be obtained in the same way); 3, establishing a feature block according to the feature points, calculating a texture deformation energy coefficient matrix, and finally obtaining the texture deformation energy parameter ks - final by PCA (Principal Component Analysis); and 4, inputting final features, namely using k final = kd - final + k alpha - final + ks - final as the training data of an RBF (Radial Basis Function) nerve network, and finally realizing facial expression recognition.

The invention relates to levamlodipine besylate crystals, a preparation method thereof and a brand-new medicinal composition containing the crystals. Characteristic peaks in an X-ray powder diffraction pattern obtained by measuring the levamlodipine besylate crystals by using Cu-K alpha rays are displayed as 8.0, 12.1, 15.4, 17.0, 19.8, 21.6, 23.0, 24.3, 25.7, 27.4, 30.7 and 33.5 degrees at 2 theta. The medicinal composition comprises the levamlodipine besylate crystals and pharmaceutically acceptable excipients, wherein the pharmaceutically acceptable excipients are microcrystalline cellulose, sodium starch glycolate and magnesium stearate. The crystals improve the dissolubility of levamlodipine besylate; and tablets prepared from the crystals have improved bioavailability.

The invention provides nanometer iron trioxide as well as a preparation method and a purpose of the nanometer iron trioxide. The nanometer iron trioxide has the following structural formula of alpha-Fe2O3, and X-ray powder diffractions obtained through measurement by using a Cu-K alpha ray via the nanometer iron trioxide have characteristic peaks through display when 2 theta is 24.1 degrees, 34.4 degrees, 36.0 degrees, 41.2 degrees, 50.2 degrees, 53.3 degrees, 57.6 degrees, 62.2 degrees and 63.7 degrees. When the nanometer iron trioxide provided by the invention is adopted for carrying out sewage treatment, the advantage of high sewage treatment efficiency is realized, in addition, the nanometer iron trioxide is solid, the reproducible performance is good, and the repeated utilization can be realized, so the sewage treatment cost can be reduced, and in addition, the advantage of simplicity in operation is also realized.

A nickel-series rechargeable battery whose cathode active material comprising a material containing an amorphous phase-bearing nickel hydroxide particulate which in X-ray diffraction using K alpha -rays of Cu as a radiation source, has a diffraction peak of a (001) face appeared near a diffraction angle 2 theta = 19 DEG having a half-value width of more than 1.2 DEG and has a diffraction peak of a (101) face appeared near a diffraction angle 2 theta = 38 DEG having a half-value width of more than 1.5 DEG . A process for the production of said rechargeable battery is also provided.

The invention discloses a novel omeprazole sodium compound. Characteristic peaks of the omeprazole sodium compound in an X-ray powder diffraction pattern obtained through Cu-K alpha-ray measurement are displayed when 2 theta is 3.2, 5.9, 7.6, 9.2, 10.5, 10.6, 12.3, 16.2, 18.2, 20.8, 23.4, 27.1, 30.4, 32.3 and 34.6. The omeprazole sodium compound has a new crystal form different from the prior art, has the thermodynamic stability higher than that with known crystal form, and has the advantage of not absorbing moisture basically. The invention also discloses a medicinal composition, which comprises the novel omeprazole sodium compound. Omeprazole sodium freeze-dried powder injection can be directly prepared under the condition of not adding lyoprotectants, and the omeprazole sodium freeze-dried powder injection has the advantages of high stability and high re-dissolubility.

The invention relates to the field of medicine and discloses a microcrystal catechin and a preparation method thereof. The microcrystal catechin is characterized by spectral signatures of x-ray powder diffraction which uses Cu-K alpha radiation and is expressed at the angle 2 theta. The preparation method comprises the five procedures of steaming, membrane technology, organic solvent extraction, solvent recovery, and concentrating and drying. The microcrystal catechin has stable quality, long shelf life, good effects in treating hyperlipaemia and cardiovascular and cerebrovascular diseases, excellent oxidation resisting property and the excellent functions of diminishing inflammations, killing bacteria, clearing radicals, resisting tumors, resisting mutations, lowering blood fat and preventing atherosis. The microcrystal catechin is a valuable nature drug and has a wide clinic application prospect.

The invention relates to the technical field of medicines, and particularly relates to a gastrodin compound, a preparation method and a preparation thereof. An X-ray powder diffraction spectrum of the gastrodin compound, measured by using a Cu-K alpha ray, is shown as a figure 1. The preparation is of a tablet, a capsule, an injection and a powder injection. The gastrodin compound provided by the invention is good in stability, difficult in absorbing moisture, and better in comprehensive physical and chemical properties; and the gastrodin preparation, especially gastrodin injection, is good in storage stability, difficult in absorbing moisture, and high in bioavailability; and the medication safety of a patient is greatly improved.

The invention provides an aztreonam compound. The structural formula of the aztreonam compound is as shown in the specification, and an X-ray powder diffraction spectrum of the aztreonam compound, which is obtained by using Cu-K alpha rays to measure, is as shown in Figure 1. The invention further provides a preparation method of the aztreonam compound and a pharmaceutical composition containing the aztreonam compound. The formulations of an aztreonam medicament are of sterile powder for injection and freeze-dried powder for injection. Compared with the prior art, the aztreonam compound and the pharmaceutical composition thereof, provided by the invention, have the advantages of better stability in storage and flowability, and can greatly improve the medication safety of patients.

The invention relates to a cefmenoxime hydrochloride composition for injection which consists of 10 parts by weight of cefmenoxime hydrochloride and 1.5 to 2.5 parts by weight of anhydrous sodium carbonate, preferably 10 parts by weight of cefmenoxime hydrochloride and 1.75 to 1.8 parts by weight of anhydrous sodium carbonate. The cefmenoxime hydrochloride is crystal, having characteristic peaks at the diffraction angles 2 theta of 6.0 degrees, 7.4 degrees, 11.0 degrees, 12.2 degrees, 17.5 degrees, 19.8 degrees, 21.6 degrees, 24.8 degrees and 27.7 degrees in the X-ray powder diffraction measured using a Cu K-alpha ray. The main crystal size of cefmenoxime hydrochloride is 30 to 45 microns and the crystal size distribution width is 25 to 75 microns. The cefmenoxime hydrochloride composition of the invention is in the dosage form of injection which is dissolved quickly, suitable for clinic application, good in stability and reliable in safety.

The invention relates to adefovir dipivoxil anhydrous crystallisate. It is characterized in that : XRD: radiating with Cu-k alpha , x ray powder diffraction spectrum expressed in 2 theta having characteristic absorption peak at 3.2,6.5,8.6, 15.7,19.6,21.6, DSC: DSC converting due to absorbing heat at 80 degree; infrared absorption spectrum : KBr pellet , characteristic absorption peak being at 3287cm-1,3175cm-1,1753cm-1,1254cm-1,1147 cm-1,1025cm-1,970cm-1. The present invention also discloses adefovir dipivoxil anhydrous crystallisate preparation method and its pharmaceutical composition. The inventive adefovir dipivoxil anhydrous crystallisate dissolves quicker than 102 degree crystal form, is high in dissolution, and is stable relative to 94 degree crystal form and not easy to be hygroscopic.

The invention discloses a method for determining centrifugal pump full-condition theoretical lifts based on internal flow measurement. The process of the method includes using internal unsteady flow dynamic rules under different working conditions of a performance intercross valuation (PIV) experiment measurement centrifugal pump; calculating theoretical lifts of the centrifugal pump under different working conditions; using an overall optimization algorithm or combination to solve flow angle coefficients under the different working conditions, performing PIV measurement on internal flows of centrifugal pumps at different specific speeds and obtaining different flow angle coefficients k alpha 1, k alpha 2 and k alpha 3 at the different specific speeds and under the different working conditions, and utilizing a unitary linear regression method to build a relation between the flow angle coefficients and the specific speeds under the different working conditions and further build a centrifugal pump full-condition theoretical lift formula. According to the method, the centrifugal pump full condition theoretical lifts under the different working conditions can be calculated accurately, and a centrifugal pump full condition energy performance calculation model is built on the basis to optimally design a prior pump.

The present invention relates to the field of medicinal chemistry, and particularly relates to a novel polymorph of safinamide mesylate salt, that is a novel polymorph B, and a preparation method therefor, and also relates to a pharmaceutical composition containing the novel polymorph and applications thereof in treating Parkinson's disease. When the polymorph B of safinamide mesylate salt is under radiation of Cu-K alpha, diffraction of X-ray powder represented by 2 theta has diffraction peaks at 7.82, 8.51, 13.01, 17.82, 18.71, 20.37, 21.98, and 22.90.

Belonging to the technical field of medicines, the invention particularly relates to a Tropisetron hydrochloride compound, its preparation method, and a pharmaceutical composition containing the same. The Tropisetron hydrochloride compound has a structural formula shown as formula (I), wherein, the Tropisetron hydrochloride compound adopts Cu-K alpha ray for characteristic X ray powder determination, the X ray powder atlas is as shown in figure 1. Compared with the prior art, the Tropisetron hydrochloride compound provided in the invention has a different crystal form, which has good stability and improved liquidity at the same time, thus improving the preparation quality.

The invention relates to the field of pharmaceutical chemistry, specifically to a new crystal form of R(+)-thioctic acid-L-lysinate, namely its crystal form I and its preparation method. The invention also relates to a pharmaceutical composition containing the new crystal form and an application of the pharmaceutical composition in the preparation of drugs for treating paresthesia caused by diabetic peripheral neuropathy. By the use of Cu-K alpha radiation, the X-ray power diffraction of R(+)-thioctic acid-L-lysinate crystal form I has diffraction peaks at 5.012, 7.589, 10.072, 12.549, 15.036, 16.688, 18.627, 19.356, 25.064 and 27.611 when expressed with 2 theta degrees, wherein the error range of 2 theta value is +/- 0.2.

The present invention provides a C-type crystal form of ceritinib. In an X-ray powder diffraction pattern obtained by use of Cu-K alpha ray measurement, the C-type crystal form of the ceritinib has characteristic peaks at an 2Theta angle of 4.9 degrees, 9.4 degrees, 9.9 degrees, 12.2 degrees, 13.7 degrees, 14.2 degrees, 14.4 degrees, 14.9 degrees, 15.6 degrees, 16.5 degrees, 17.0 degrees, 17.7 degrees, 18.9 degrees, 20.6 degrees, 22.0 degrees, 25.0 degrees, 26.6 degrees, 25.9 degrees and 28.5 degrees. The present invention also provides a preparation method for the C-type crystal form of the ceritinib, and an application. The C-type crystal form of the ceritinib provided by the present invention is high in crystallinity and high in water solubility. The preparation method for the C-type crystal form of the ceritinib is simple, liable to control, liable to prepare the C-type crystal form, and good in reproducibility; and the oral bioavailability of ceritinib is remarkably improved.

A powderous lithium transition metal oxide having a layered crystal structure Li1+aM1-aO2+-b M'k Sm with -0.03 < a < 0.06, 0 <= m <= 0.6, m being expressed in mol%, M being a transition metal compound, consisting of at least 95% of either one or more elements of the group Ni, Mn, Co and Ti; M' being present on the surface of the powderous oxide, and consisting of either one or more elements of the group Ca, Sr, Y, La, Ce and Zr, wherein: either k = 0 and M = Ni1-c-dMncCOd, with 0<c<1, and 0<d<1; or 0.015 < k < 0.15, k being expressed in wt% of said lithium transition metal oxide; characterized in that for said powderous oxide, the X-ray diffraction peak at 44.5 +- 0.3 degree, having as index 104, measured with K alpha radiation, has a FWHM value of <= 0.1 degree. By optimizing the sintering temperature of the metal oxide the FWHM value can be minimized.

An aluminum oxide deposited film of the invention, comprising a substrate film and an aluminum oxide deposit layer of which the peel strength to the substrate film in a wet state is at least 0.3 N/15mm, has an oxygen permeability of not more than 40 ml/m<2>.day.MPa and a water vapor permeability of not more than 4.0 g/ m<2>.day. The deposition ratio (A/B) of a fluorescent X-ray intensity (A) kcps (aluminum K alpha -ray) of the aluminum oxide deposited film (1) to a fluorescent X-ray intensity (B) kcps (aluminum K alpha -ray) of an aluminum deposited film (2) obtained without feeding oxygen is (A/B) <= 0.85.

The invention belongs to the technical field of medicines and particularly relates to an acetylcysteine compound and an acetylcysteine solution being used for inhalation and containing the same. The acetylcysteine compound is a hydrate crystal, and the molecular formula of the acetylcysteine compound is C5H9NO3S*H2O. An X-ray powder diffraction spectrogram obtained through measurement of the acetylcysteine compound by using Cu-K alpha rays is shown in figure 1. According to the new-crystal-form acetylcysteine compound, the hygroscopicity of the compound can be significantly improved; the acetylcysteine solution which is used for inhalation and prepared from the new-crystal-form acetylcysteine compound is convenient to use, focus-targeted, fast in acting and good in curative effect.

The invention belongs to the technical field of medicine and discloses a tofacitinib crystal form compound and a preparation method thereof. The X-ray powder diffraction spectrum shown by the 2 theta +-0.2 degree diffraction angle shows characteristic diffraction peaks at 2.42 degrees, 3.25 degrees, 4.23 degrees, 5.04 degrees, 6.12 degrees, 7.08 degrees, 8.02 degrees, 9.72 degrees, 10.63 degrees, 12.90 degrees, 14.35 degrees, 15.71 degrees, 17.82 degrees, 18.34 degrees, 19.24 degrees, 22.46 degrees, 24.56 degrees, 26.62 degrees, 30.75 degrees and 32.45 degrees, and the X-ray powder diffraction spectrum obtained by Cu-K alpha ray measurement and shown by the figure I is totally different from the prior art. The tofacitinib crystal form compound has better water solubility and high stability, the preparation method is simple and easy to operate, the medication safety is improved greatly after the compound is prepared into a drug composition, and the compound is very suitable for clinical application.

The invention relates to a riboflavin sodium phosphate compound, which exists in a crystal form. X-ray powder diffraction measured by Cu-K alpha rays shows that characteristic peaks exist at 2Theta of 12.4 degrees, 13.3 degrees, 14.7 degrees, 16.1 degrees, 16.9 degrees, 18.1 degrees, 18.9 degrees, 19.9 degrees, 20.9 degrees, 21.5 degrees, 22.7 degrees, 24.0 degrees, 24.7 degrees, 25.4 degrees, 26.7 degrees, 27.4 degrees and 28.2 degrees. The riboflavin sodium phosphate compound has main particle sizes of 5 to 15 mu m, preferably 6 to 12 mu m, and the distribution width of 2 to 20 mu m, preferably 3 to 18 mu m. A stability experiment shows that the riboflavin sodium phosphate crystal compound has high stability and better water solubility.

The invention relates to a novel crystal form of rabeprazole sodium aquo-complex and a preparation method of the novel crystal form. The novel crystal form is called the Z-type crystal. The Z-type crystal of the rabeprazole sodium aquo-complex is characterized in that in the X-ray powder diffraction pattern expressed by Cu-K alpha radiation and a 2theta+/-0.2DEG diffraction angle, the Z-type crystal has characteristic diffraction peaks at 9.3, 10.7, 18.2, 19.6, 21.2, 23.0, 27.2 and 29.9.